Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018099 (gout)
 5,192 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It is fairly frequent to encounter hyperlipemia on a rheumatic unit. Firstly the symptoms of certain idiopathic hyperlipemias sometimes include rheumatic changes. The latter include firstly, arthritis and tendinitis, above all observed in Type II hyperlipoproteinemia but also mentionned in Type IV, and secondly, exceptional bony lesions (generally of xanthoma type) which seem to occur exclusively in severe hyperglyceridemia. A few bone and joint diseases, such as gout or aseptic necrosis, frequently coexist with dyslipemia. Furthermore, various diseases may be simultaneously responsible for secondary hyperlipemia and involvement of the locomotor apparatus. Finally, the iatrogenic manifestations of the locomotor system appear mainly due to hypolipemic drugs, e.g. the muscle disorders seen in a few patients treated with clofibrate.
Sem Hop
PMID:[Hyperlipemias and their manifestations in the rheumatological sphere]. 19 31

Serum urate levels and history of gout were observed from 4663 men aged 20-44 who were employed by a Parisian government agency. Serum urate levels, mean value 62,8 mg/l (374 mu mol/l), did not vary with age but were strongly correlated with weight. For constant weight, urate levels decreased with age. By our definition: typical history of gout and either efficacity of colchicine during an attack or serum urate level over 70 mg/l (417 mu mol/l) at examination, there were 57 cases of gout, giving a prevalence of 1,1% among men 35-39 and 2,0% among men 40-44 years old. Using the definition by the New York criteria which do not include serum urate level, there were 51 cases of gout, giving a prevalence of 1,5% in the 35-44 year age group. This is about 3 times the prevalence found by O'Sullivan, using the same criteria, in an American town. the higher serum urate levels in the present study may account for much of this difference. The incidence of new cases of gout was estimated to be 1,6% over 5 years for men 40-44 years old. The site was the great toe in 57% of gouty men with only one attack and in 92% of those with more than one attack. It was not related to the amount of standing or activity at work. Comparison with a study made 7 years earlier showed an augmentation in serum urate values and probably in prevalence of gout. These results are discussed in terms of dietary modification over this time period.
Sem Hop
PMID:[Serum urate and gout in 4663 young male workers (author's transl)]. 626 15

The precipitation of monosodium urate crystals within joints triggers an acute inflammatory reaction that is the root cause of gout. The inflammation induced by the injection of MSU crystals into the murine air pouch for 1, 3, and 5 h was examined by iTRAQ-based proteomic profiling. The iTRAQ-labeled peptides were fractionated by SCX, basic-RP or solution-IEF, followed by LC-MS/MS analysis. A total of 951 proteins were quantified from the total combined fractions. Among them, 317 proteins exhibited a differential expression, compared to that of the controls at one time point or more. The majority of the differentially expressed proteins were found in the sample after a 5-h MSU treatment. Western blot revealed that the expression levels of cathelin-related antimicrobial peptide and S100A9 were positively correlated with the time-course treated with MSU. Further analysis of GeneGO pathway demonstrated that these differentially expressed proteins are primarily related to the immune-related complement system and the tricarboxylic acid cycle. Moreover, seven genes from the TCA cycle were found to be significantly downregulated at the transcriptional level and its correlation with gout and possible therapeutic applications are worth further investigation. Last, we found that pyruvate carboxylation could be potential targets for antigout treatment.
 ...
PMID:Differential proteomics of monosodium urate crystals-induced inflammatory response in dissected murine air pouch membranes by iTRAQ technology. 2620 48